Latest SUPERSTRING CAPITAL MANAGEMENT LP Stock Portfolio
SUPERSTRING CAPITAL MANAGEMENT LP Performance:
2024 Q3: 7.72%YTD: -15.57%
Performance for 2024 Q3 is 7.72%, and YTD is -15.57%.
About SUPERSTRING CAPITAL MANAGEMENT LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, SUPERSTRING CAPITAL MANAGEMENT LP reported an equity portfolio of $114.2 Millions as of 30 Sep, 2024.
The top stock holdings of SUPERSTRING CAPITAL MANAGEMENT LP are ZLAB, CYTK, TERN. The fund has invested 13.2% of it's portfolio in ZAI LAB LTD and 10% of portfolio in CYTOKINETICS INC.
The fund managers got completely rid off KEROS THERAPEUTICS INC (KROS), ARCELLX INC (ACLX) and ARROWHEAD PHARMACEUTICALS IN (ARWR) stocks. They significantly reduced their stock positions in TOURMALINE BIO INC, CORBUS PHARMACEUTICALS HLDGS (CRBP) and BIOMEA FUSION INC (BMEA). SUPERSTRING CAPITAL MANAGEMENT LP opened new stock positions in STRUCTURE THERAPEUTICS INC, ORIC PHARMACEUTICALS INC (ORIC) and INSTIL BIO INC (TIL). The fund showed a lot of confidence in some stocks as they added substantially to NOVOCURE LTD (NVCR), TANGO THERAPEUTICS INC (TNGX) and FATE THERAPEUTICS INC (FATE).
The top stock holdings of SUPERSTRING CAPITAL MANAGEMENT LP are ZLAB, CYTK, TERN. The fund has invested 13.2% of it's portfolio in ZAI LAB LTD and 10% of portfolio in CYTOKINETICS INC.
The fund managers got completely rid off KEROS THERAPEUTICS INC (KROS), ARCELLX INC (ACLX) and ARROWHEAD PHARMACEUTICALS IN (ARWR) stocks. They significantly reduced their stock positions in TOURMALINE BIO INC, CORBUS PHARMACEUTICALS HLDGS (CRBP) and BIOMEA FUSION INC (BMEA). SUPERSTRING CAPITAL MANAGEMENT LP opened new stock positions in STRUCTURE THERAPEUTICS INC, ORIC PHARMACEUTICALS INC (ORIC) and INSTIL BIO INC (TIL). The fund showed a lot of confidence in some stocks as they added substantially to NOVOCURE LTD (NVCR), TANGO THERAPEUTICS INC (TNGX) and FATE THERAPEUTICS INC (FATE).
SUPERSTRING CAPITAL MANAGEMENT LP Annual Return Estimates Vs S&P 500
Our best estimate is that SUPERSTRING CAPITAL MANAGEMENT LP made a return of 7.72% in the last quarter. In trailing 12 months, it's portfolio return was 14.98%.
New Buys
| Ticker | $ Bought |
|---|---|
| structure therapeutics inc | 9,965,090 |
| oric pharmaceuticals inc | 9,732,600 |
| instil bio inc | 7,239,930 |
| capricor therapeutics inc | 5,131,050 |
| zenas biopharma inc | 1,888,360 |
| immunovant inc | 354,864 |
| cullinan therapeutics inc | 348,862 |
| eliem therapeutics inc | 172,164 |
New stocks bought by SUPERSTRING CAPITAL MANAGEMENT LP
Additions
| Ticker | % Inc. |
|---|---|
| novocure ltd | 487 |
| tango therapeutics inc | 418 |
| fate therapeutics inc | 194 |
| zai lab ltd | 191 |
| terns pharmaceuticals inc | 40.98 |
| cytokinetics inc | 15.01 |
| bridgebio pharma inc | 3.11 |
Additions to existing portfolio by SUPERSTRING CAPITAL MANAGEMENT LP
Reductions
| Ticker | % Reduced |
|---|---|
| tourmaline bio inc | -69.44 |
| legend biotech corp | -60.87 |
| corbus pharmaceuticals hldgs | -55.02 |
| biomea fusion inc | -50.00 |
| allogene therapeutics inc | -30.7 |
| spyre therapeutics inc | -18.18 |
| nkarta inc | -15.49 |
| 89bio inc | -12.52 |
SUPERSTRING CAPITAL MANAGEMENT LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| cytomx therapeutics inc | -1,404,850 |
| allakos inc | -940,578 |
| karyopharm therapeutics inc | -463,719 |
| pyxis oncology inc | -1,603,510 |
| atyr pharma inc | -488,324 |
| marinus pharmaceuticals inc | -306,377 |
| arrowhead pharmaceuticals in | -2,888,350 |
| mersana therapeutics inc | -221,247 |
SUPERSTRING CAPITAL MANAGEMENT LP got rid off the above stocks
Sector Distribution
SUPERSTRING CAPITAL MANAGEMENT LP has about 85.3% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 85.3 |
| Others | 14.7 |
Market Cap. Distribution
SUPERSTRING CAPITAL MANAGEMENT LP has about 13.5% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 38.7 |
| MID-CAP | 21.2 |
| UNALLOCATED | 14.7 |
| LARGE-CAP | 13.5 |
| MICRO-CAP | 12 |
Stocks belong to which Index?
About 53.7% of the stocks held by SUPERSTRING CAPITAL MANAGEMENT LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 53.7 |
| Others | 46.3 |
SUPERSTRING CAPITAL MANAGEMENT LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of SUPERSTRING CAPITAL MANAGEMENT LP
SUPERSTRING CAPITAL MANAGEMENT LP has 27 stocks in it's portfolio. About 76.1% of the portfolio is in top 10 stocks. NKTX proved to be the most loss making stock for the portfolio. TIL was the most profitable stock for SUPERSTRING CAPITAL MANAGEMENT LP last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AGLE | spyre therapeutics inc | 0.96 | 37,287 | 1,096,610 | reduced | -18.18 | ||
| ALLK | allakos inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALLO | allogene therapeutics inc | 1.17 | 478,115 | 1,338,720 | reduced | -30.7 | ||
| ARWR | arrowhead pharmaceuticals in | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BBIO | bridgebio pharma inc | 5.05 | 226,684 | 5,771,380 | added | 3.11 | ||
| BGNE | beigene ltd | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BMEA | biomea fusion inc | 0.74 | 83,554 | 843,895 | reduced | -50.00 | ||
| CABA | cabaletta bio inc | 0.54 | 131,795 | 622,072 | reduced | -5.79 | ||
| CAPR | capricor therapeutics inc | 4.49 | 337,347 | 5,131,050 | new | |||
| CGEM | cullinan therapeutics inc | 0.30 | 20,840 | 348,862 | new | |||
| CMPS | compass pathways plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CRBP | corbus pharmaceuticals hldgs | 0.46 | 25,401 | 524,023 | reduced | -55.02 | ||
| CTMX | cytomx therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CYTK | cytokinetics inc | 9.97 | 215,798 | 11,394,100 | added | 15.01 | ||
| ELYM | eliem therapeutics inc | 0.15 | 33,824 | 172,164 | new | |||
| ETNB | 89bio inc | 3.86 | 595,203 | 4,404,500 | reduced | -12.52 | ||
| EYPT | eyepoint pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| FATE | fate therapeutics inc | 4.49 | 1,466,930 | 5,134,270 | added | 194 | ||
| IMVT | immunovant inc | 0.31 | 12,447 | 354,864 | new | |||